GREENWOOD VILLAGE, Colo., Nov. 19, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) CEO, Michael Macaluso, remarked "We are not aware of any basis for an investigation of Ampio. We note that the law firm's press release/solicitation does not contain any facts whatsoever that would explain why they are conducting an investigation. Any objective review of Ampio's promising clinical trial results and subsequent stock performance achieved over the past year will conclude that the company is performing well. Consequently we believe this provocative solicitation is not intended to benefit shareholders and we encourage all interested parties to form their own conclusions about the motivation behind this law firm's actions."
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.
Forward Looking Statements
Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, under Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contact: Rick Giles, Director of Investor Relations, Ampio Pharmaceuticals, Inc. Direct: (720) 437-6530, Email: firstname.lastname@example.org
|SOURCE Ampio Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved